Stryker (NYSE:SYK) Stock Gets Price Target Trim from TD Cowen

Stryker (NYSE:SYK) had its target price reduced by stock analysts at TD Cowen from $298.00 to $290.00 in a report released on Friday, Benzinga reports. The firm currently has a “hold” rating on the medical technology company’s stock. TD Cowen‘s price target would suggest a potential downside of 0.54% from the stock’s previous close.

Several other equities analysts have also recently weighed in on SYK. Citigroup reissued a “market outperform” rating on shares of Stryker in a research note on Friday. Piper Sandler decreased their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. BTIG Research dropped their target price on shares of Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a report on Friday. Barclays reduced their price target on Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a report on Friday. Finally, Truist Financial lowered their price target on Stryker from $340.00 to $310.00 and set a “hold” rating on the stock in a research report on Tuesday, October 6th. Seventeen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $357.64.

Stryker Trading Down 6.5%

Shares of NYSE:SYK traded down $20.19 during midday trading on Friday, hitting $291.56. The company had a trading volume of 6,437,128 shares, compared to its average volume of 2,467,420. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a market cap of $111.83 billion, a price-to-earnings ratio of 30.21, a PEG ratio of 1.96 and a beta of 0.78. The firm has a fifty day simple moving average of $293.56 and a 200 day simple moving average of $324.86. Stryker has a 12 month low of $267.00 and a 12 month high of $389.33.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. During the same quarter in the previous year, the business earned $3.19 earnings per share. The company’s revenue was up 7.6% on a year-over-year basis. On average, analysts predict that Stryker will post 14.93 EPS for the current year.

Insider Transactions at Stryker

In related news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 over the last three months. 4.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stryker

Several large investors have recently added to or reduced their stakes in SYK. Gables Capital Management Inc. purchased a new stake in Stryker in the 2nd quarter worth approximately $25,000. Kilter Group LLC bought a new position in Stryker during the second quarter valued at approximately $25,000. Highland Investment Advisors LLC bought a new stake in shares of Stryker in the 2nd quarter worth approximately $25,000. Cornerstone Financial Management LLC grew its holdings in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Finally, Compass Financial Management LLC bought a new stake in Stryker in the second quarter worth $27,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Analysts remain broadly constructive despite lowering estimates. RBC, Barclays, Citizens JMP and BTIG reduced their price targets but maintained Outperform, Overweight, Market Outperform or Buy ratings, indicating potential upside from recent levels. RBC price target article
• Neutral Sentiment: Third-quarter revenue increased 7.6% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19. Management highlighted strength in MedSurg, margin improvement and continued investment in robotic surgery, but those positives were overshadowed by weaker areas of the business. Stryker third-quarter results
• Negative Sentiment: Stryker missed Wall Street expectations, reporting $3.52 in EPS versus approximately $3.55–$3.56 expected and $6.52 billion in revenue versus about $6.62 billion expected. The company also cut its 2026 forecast to 6.5%–7.0% organic sales growth and $14.80–$14.90 in adjusted EPS, down from prior guidance of 8.3%–9.3% sales growth and $14.95–$15.10 EPS. Stryker earnings and revenue miss
• Negative Sentiment: Investors remain concerned that weaker joint-replacement demand, supply disruptions and a previously unresolved manufacturing issue affecting peripheral vascular products could pressure sales into 2027. The disclosure has prompted scrutiny of the company’s execution, particularly as a new CEO takes over. Stryker peripheral vascular problems
• Negative Sentiment: Canaccord downgraded Stryker from Buy to Hold and cut its price target from $385 to $300, reinforcing concerns that the guidance reduction reflects more than a temporary earnings setback. Canaccord Stryker rating

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.